BioStock – Connecting Innovation and Capital

Respiratorius gets green light for PK study

13 January, 2022

Key steps taken by BiBBInstruments in 2021

13 January, 2022

Cereno Scientific eyes an eventful 2022

12 January, 2022

Immunicum can look back on a transformative 2021

11 January, 2022

Curasight targets prostate cancer with theranostic approach

7 January, 2022

STUDIO

BioStock Studio: Cyxone comments on the Covid-19 study result

8 December, 2021

Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data...

BioStock Studio: SynAct Pharma comments on the promising study results in...

3 December, 2021

BioStock Studio: CLS’ CEO about Q3 and the road ahead

22 November, 2021

BioStock Studio: Cereno Scientific’s CEO comments on the third quarter

17 November, 2021

BioStock studio: Saniona celebrates a decade of progress

11 November, 2021

Respiratorius gets green light for PK study

13 January, 2022

Respiratorius is ready to initiate a pharmacokinetic phase I study with VAL001. The aim...

Key steps taken by BiBBInstruments in 2021

13 January, 2022

Despite some turbulence for BiBBInstruments in the early parts of 2021, the Swedish medtech...

Cereno Scientific eyes an eventful 2022

12 January, 2022

Immunicum can look back on a transformative 2021

11 January, 2022

Curasight targets prostate cancer with theranostic approach

7 January, 2022

Saniona starts 2022 with three clinical trials

Saniona begins 2022 with three clinical trials ongoing

4 January, 2022

EVENT

Strong opening to BioStock Life Science Summit 2019 – see videos...

6 July, 2021

BLSS 2019 videos: Innovation takes centre stage in the second round...

6 July, 2021

BLSS 2019 videos: both bio- and medtech on display in third...

6 July, 2021

A triplet of pioneers in fourth round of presentations at BLSS...

6 July, 2021

Avatar BioStock News @BioStock_News·

18 Dec

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab https://mfn.se/a/bioinvent-international/bioinvent-announces-positive-early-data-from-ongoing-solid-cancer-trial-of-bi-1206-in-combination-with-pembrolizumab @BioInvent #lifesciences

Reply on Twitter 1472126442548957185 Retweet on Twitter 1472126442548957185 Like on Twitter 14721264425489571852 Twitter 1472126442548957185

Avatar BioStock News @BioStock_News·

15 Dec

RhoVac's co-founder and board member sells a fraction of his shares to cover taxes on holdings #BioStock_News #LifeScience

https://news.cision.com/rhovac/r/rhovac-s-co-founder-and-board-member-sells-a-fraction-of-his-shares-to-cover-taxes-on-holdings,c3472448

Reply on Twitter 1471050754182033408 Retweet on Twitter 1471050754182033408 Like on Twitter 1471050754182033408 Twitter 1471050754182033408

Avatar BioStock News @BioStock_News·

10 Dec

Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients #BioStock_News #LifeScience

https://news.cision.com/curasight/r/phase-ii-study-demonstrates-prognostic-value-of-upar-pet-in-head-and-neck-cancer-patients,c3469220

Reply on Twitter 1469185934197407747 Retweet on Twitter 1469185934197407747 Like on Twitter 1469185934197407747 Twitter 1469185934197407747

Ladda fler

STUDIO

RECOMMENDED READING

EVENT